Latest Cryo-Cell International Inc. Stories
OLDSMAR, Fla., Nov. 13, 2012 /PRNewswire/ -- Cryo-Cell International (OTC:QB Markets Group Symbol: CCEL) announced the appointment of Wayne Green, Ph.D., as director of flow cytometry. Dr. Green is responsible for overseeing the highly specialized method for analyzing and sorting blood cells in Cryo-Cell's state-of-the art laboratory. Flow cytometry studies enable the lab to separate stem cells from other blood cells in umbilical cord and menstrual specimens. (Photo:...
Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL), the company that in 1992, became the first to separate and store stem cells, today announced financial results for the third quarter ended August 31, 2012. Oldsmar, Florida (PRWEB) October 15, 2012 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) today announced financial results for the third quarter ended August 31, 2012. For the quarter ended August 31, 2012, the Company...
SAN FRANCISCO, July 6, 2012 /PRNewswire/ -- Ki Yong Choi, who owns approximately 19.6% of the outstanding shares of Cryo-Cell International, Inc. (OTCBB: CCEL), today issued the following letter to stockholders of Cryo-Cell. Dear Fellow Cryo-Cell Stockholder: On July 5, 2012 Cryo-Cell International, Inc. issued a press release which included the following quote by Mr. George Gaines, chairman of the company's Compensation Committee, "David and Mark Portnoy know exactly what it takes...
SAN FRANCISCO, July 5, 2012 /PRNewswire/ -- Ki Yong Choi, the largest stockholder of Cryo-Cell International, Inc. (OTCBB: CCEL) with approximately 19.6% of the company's outstanding shares, today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading proxy advisory firm, issued a report on July 2, 2012 recommending that Cryo-Cell stockholders vote on the GOLD proxy card for ALL six of Mr. Choi's Board nominees. In response to the Glass Lewis report, Mr. Choi...
Cryo-Cell International Chairman David Portnoy updated shareholders with results achieved by the current Board's leadership, which is being challenged for control of the company by former Board members. OLDSMAR, Fla. (PRWEB) July 03, 2012 Cryo-Cell International, Inc. [OTCQB Symbol: CCEL] updated shareholders with results achieved by the current Board’s leadership, which is being challenged for control of the company by previous Board members Ki Yong Choi and his brother-in-law....
TAMPA, Fla., July 3, 2012 /PRNewswire/ -- On behalf of Saneron CCEL Therapeutics, Inc., President and COO, Nicole Kuzmin-Nichols, MBA, expressed strong support today for the Cryo-Cell International, Inc. (OTCQB: CCEL) current executive management in response to a proxy bid by a former Board member. Cryo-Cell is a major shareholder in Saneron, a Tampa based biotechnology research and development company that was spun out from the University of South Florida to develop cellular...
SAN FRANCISCO, June 26, 2012 /PRNewswire/ -- Ki Yong Choi, who owns 2,186,568 shares of common stock of Cryo-Cell International, Inc. (OTCBB: CCEL), or approximately 19.6% of the company's outstanding shares, today issued the following letter to stockholders of Cryo-Cell. ELECT A BOARD THAT IS COMMITTED TO ACTING IN THE BEST INTERESTS OF ALL STOCKHOLDERS THE CURRENT BOARD APPROVED WHAT I BELIEVE TO BE EGREGIOUSLY COSTLY EMPLOYMENT CONTRACTS, EXCESSIVE STOCKHOLDER DILUTION...
Repeated injections of human umbilical cord blood cells improved motor neuron survival, delayed disease progression and increased lifespan Oldsmar, FL (PRWEB) March 06, 2012 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) today announced results of a study published last month in PloS ONE from University of South Florida researchers and colleagues from Saneron CCEL Therapeutics, Inc. and the Ribeirao Preto School of Medicine at the University of Sao Paulo, Brazil. The...
OLDSMAR, Fla., Feb. 29, 2012 /PRNewswire/ -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for its fiscal year 2011. "Cryo-Cell fiscal 2011 results are indicative of a company that is in the process of making many organizational and operational improvements," stated David Portnoy, Cryo-Cell's Chairman and Co-CEO. "Although the...
Collaboration will evaluate menstrual stem cells for future potential diabetes therapy Oldsmar, Fla (PRWEB) February 07, 2012 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) and Stanford University announced signing a material transfer agreement to test the efficacy of mesenchymal-like stem cells derived from menstrual blood (MenSCs) in a model of pancreatic islet transplantation for type 1 diabetes treatment. Specifically, the menstrual blood stem cells provided by...
